Patients who contracted COVID-19 are twice as likely to have depressive symptoms, with 67% of these experiencing clinically significant anxiety 13 months after the acute phase, compared to a control group, British researchers reported in Scientific Reports. These results are related, among other factors, to the affectation of the intestinal microbiota caused by SARS-CoV-2; inflammation of the intestinal mucosa resulting from the release of inflammatory cytokines caused by the virus itself; and obviously that this temporary dysbiosis is reinforced by the use of antibiotics in the acute phase that, as a whole, decrease the number of beneficial microorganisms that, as is known, are in charge of elaborating the precursor amino acids of the neurotransmitters related to the anxiety and depression.
Post-pandemic patients are recommended to use “DEEP BLOCK” which, in addition to being highly effective in preventing the entry of viruses such as the cause of COVID-19 and bacteria; controls the infestation and passage of sick patients from serious and critical stages to the death of people. The “DEEP BLOCK” is also designed to minimize inflammatory processes; modulate the production of inflammatory cytokines, and assist in the restoration of the intestinal microbiota, thereby reversing the inflammatory processes of the heart, and liver, and also restoring the balance of neurotransmitters to control anxiety and depression.